| Today's Big NewsNov 1, 2022 |
| By Max Bayer Lilly is exuding optimism as the race to develop a breakthrough Alzheimer's treatment hits the home stretch. The company is hoping to stay neck-and-neck with Eisai after the latter turned heads with its phase 3 lecanemab data. |
|
|
|
By Kevin Dunleavy Uptake of Pfizer’s omicron-adjusted COVID-19 booster may be progressing slowly, but after a surprisingly strong quarter, the company has bumped up its projection for COVID vaccine sales for the year by $2 billion to a total of $34 billion. Yet analysts aren't persuaded. |
By Conor Hale The deal includes an upfront cash payment of $380 per share, representing a 50% premium over Abiomed’s closing stock price the day before the announcement. |
By Paige Minemyer Open enrollment on the Affordable Care Act's exchanges is about to begin for the 10th time. Here are some of the key trends to watch. |
By Nick Paul Taylor Pfizer has halted a pivotal trial of its respiratory syncytial virus vaccine candidate early for efficacy, positioning it to file for approval by the end of the year. But with the study only meeting one of its two primary endpoints, the top-line result leaves scope to question how Pfizer will fare against AstraZeneca and Sanofi’s rival antibody. |
By Heather Landi Nearly 334,000 physicians, nurse practitioners, physician assistants and other clinicians left the workforce in 2021 due to retirement, burnout and pandemic-related stressors, according to new data. |
By Kevin Dunleavy Drug shortages aren’t going away any time soon, according to Bindiya Vakil, CEO of Resilinc, a California-based firm that helps companies from a variety of industries mitigate supply chain problems. While shortages of high-profile drugs such as Adderall and amoxicillin have garnered headlines recently, Vakil points to a recent FDA warning that has the potential for more far-reaching consequences. |
By Andrea Park As the FDA convenes an advisory committee meeting to discuss recent studies showing that many pulse oximeters are less effective when used on patients with darker skin, BioIntelliSense is getting a head start on addressing the issue. |
By Annalee Armstrong Unity Biotechnology seems to have gotten its crew together behind a common goal in ophthalmology, with the biotech announcing today that its treatment for diabetic macular edema improved vision in a mid-stage trial. |
By Heather Landi VillageMD, which is majority owned by Walgreens Boots Alliance, is exploring a potential deal to merge with medical practice Summit Health, the parent company of urgent care clinic chain CityMD, Bloomberg reported Sunday. |
By Zoey Becker Medicago, a Canadian vaccine maker that scored the first approval for a plant-based COVID-19 vaccine earlier this year, will slash 62 jobs at its Durham, North Carolina, site by the year-end. The move is part of a "new approach" to manufacturing its vaccines, Medicago's CEO Toshifumi Tada told Fierce Pharma. |
By Andrea Park In total, Stryker reported net sales of $4.5 billion. The increase was led by its MedSurg and neurotechnology division, which saw a 10% year-over-year increase to reach sales of $2.6 billion. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now.
|
|
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
